anonymous
Guest
anonymous
Guest
Bayer’s stock has taken a nosedive, now hovering around the $5 mark—marking a 20-year low! During the recent earnings call, investors vented their frustrations, demanding to know why there’s no clear mid-term strategy in sight. It raises an intriguing question: why are skilled professionals still sticking around this tumultuous ride?
Let’s be real—claiming that Nubeqa and Kerendia are exceeding expectations seems almost comical when you consider that only a third of our sales team qualifies for bonuses. With Nubeqa facing a coverage loss in Medicare Part D next year and uncertainty looming over a lifestyle menopause drug, it’s challenging to spot a silver lining!
The big question now looms: how low will the stock sink before we witness job cuts and asset sell-offs as the company struggles to stay afloat? Before anyone from management jumps in to dismiss these concerns or suggests I find a new job, let me assure you—all talented individuals already have or are looking. The reality is, those who remain might just be too complacent, underperforming, or financially comfortable to make a move.
Let’s be real—claiming that Nubeqa and Kerendia are exceeding expectations seems almost comical when you consider that only a third of our sales team qualifies for bonuses. With Nubeqa facing a coverage loss in Medicare Part D next year and uncertainty looming over a lifestyle menopause drug, it’s challenging to spot a silver lining!
The big question now looms: how low will the stock sink before we witness job cuts and asset sell-offs as the company struggles to stay afloat? Before anyone from management jumps in to dismiss these concerns or suggests I find a new job, let me assure you—all talented individuals already have or are looking. The reality is, those who remain might just be too complacent, underperforming, or financially comfortable to make a move.